Importantly, epidemiological and clinical studies have found that heterozygous NBS patients, who are clinically asymptomatic, also display an elevated risk to develop some types of malignant tumors [42], supporting the idea that NBS1 gene is a haploinsufficient oncosuppressor. This evidence concerns the gene NBN and cancer.